| Year |
Citation |
Score |
| 2014 |
Zoladz PR, Kalchik AE, Hoffman MM, Aufdenkampe RL, Lyle SM, Peters DM, Brown CM, Cadle CE, Scharf AR, Dailey AM, Wolters NE, Talbot JN, Rorabaugh BR. ADRA2B deletion variant selectively predicts stress-induced enhancement of long-term memory in females. Psychoneuroendocrinology. 48: 111-22. PMID 24997351 DOI: 10.1016/J.Psyneuen.2014.06.012 |
0.304 |
|
| 2013 |
Zoladz PR, Warnecke AJ, Woelke SA, Burke HM, Frigo RM, Pisansky JM, Lyle SM, Talbot JN. Pre-learning stress that is temporally removed from acquisition exerts sex-specific effects on long-term memory. Neurobiology of Learning and Memory. 100: 77-87. PMID 23266791 DOI: 10.1016/J.Nlm.2012.12.012 |
0.301 |
|
| 2011 |
Waterson RE, Thompson CG, Mabe NW, Kaur K, Talbot JN, Neubig RR, Rorabaugh BR. Gα(i2)-mediated protection from ischaemic injury is modulated by endogenous RGS proteins in the mouse heart. Cardiovascular Research. 91: 45-52. PMID 21349876 DOI: 10.1093/Cvr/Cvr054 |
0.301 |
|
| 2010 |
Talbot JN, Jutkiewicz EM, Graves SM, Clemans CF, Nicol MR, Mortensen RM, Huang X, Neubig RR, Traynor JR. RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects. Proceedings of the National Academy of Sciences of the United States of America. 107: 11086-91. PMID 20534514 DOI: 10.1073/Pnas.1000003107 |
0.312 |
|
| 2010 |
Talbot JN, Roman DL, Clark MJ, Roof RA, Tesmer JJ, Neubig RR, Traynor JR. Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent. Journal of Neurochemistry. 112: 1026-34. PMID 20002516 DOI: 10.1111/J.1471-4159.2009.06519.X |
0.318 |
|
| 2009 |
Talbot JN, Skifter DA, Bianchi E, Monaghan DT, Toews ML, Murrin LC. Regulation of mu opioid receptor internalization by the scaffold protein RanBPM. Neuroscience Letters. 466: 154-8. PMID 19788913 DOI: 10.1016/J.Neulet.2009.09.048 |
0.338 |
|
| 2007 |
Roman DL, Talbot JN, Roof RA, Sunahara RK, Traynor JR, Neubig RR. Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay. Molecular Pharmacology. 71: 169-75. PMID 17012620 DOI: 10.1124/Mol.106.028670 |
0.331 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2014 |
Zoladz PR, Kalchik AE, Hoffman MM, Aufdenkampe RL, Burke HM, Woelke SA, Pisansky JM, Talbot JN. Brief, pre-retrieval stress differentially influences long-term memory depending on sex and corticosteroid response. Brain and Cognition. 85: 277-85. PMID 24509087 DOI: 10.1016/J.Bandc.2014.01.010 |
0.297 |
|
| 2014 |
Zoladz PR, Peters DM, Kalchik AE, Hoffman MM, Aufdenkampe RL, Woelke SA, Wolters NE, Talbot JN. Brief, pre-learning stress reduces false memory production and enhances true memory selectively in females. Physiology & Behavior. 128: 270-6. PMID 24560841 DOI: 10.1016/J.Physbeh.2014.02.028 |
0.297 |
|
| 2007 |
Murrin LC, Talbot JN. RanBPM, a scaffolding protein in the immune and nervous systems. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 2: 290-5. PMID 18040864 DOI: 10.1007/S11481-007-9079-X |
0.293 |
|
| 2005 |
Talbot JN, Happe HK, Murrin LC. Mu opioid receptor coupling to Gi/o proteins increases during postnatal development in rat brain. The Journal of Pharmacology and Experimental Therapeutics. 314: 596-602. PMID 15860573 DOI: 10.1124/Jpet.104.082156 |
0.289 |
|
| 2011 |
Zoladz PR, Clark B, Warnecke A, Smith L, Tabar J, Talbot JN. Pre-learning stress differentially affects long-term memory for emotional words, depending on temporal proximity to the learning experience. Physiology & Behavior. 103: 467-76. PMID 21262248 DOI: 10.1016/J.Physbeh.2011.01.016 |
0.282 |
|
| 2016 |
Talbot JN, Geffert LM, Jorvig JE, Goldstein RI, Nielsen CL, Wolters NE, Amos ME, Munro CA, Dallman E, Mereu M, Tanda G, Katz JL, Indarte M, Madura JD, Choi H, et al. Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening. Pharmacology, Biochemistry, and Behavior. PMID 27569602 DOI: 10.1016/J.Pbb.2016.08.007 |
0.279 |
|
| 2020 |
Urasaki Y, Beaumont C, Workman M, Talbot JN, Hill DK, Le TT. Fast-Acting and Receptor-Mediated Regulation of Neuronal Signaling Pathways by Copaiba Essential Oil. International Journal of Molecular Sciences. 21. PMID 32218156 DOI: 10.3390/Ijms21072259 |
0.279 |
|
| 2020 |
Urasaki Y, Beaumont C, Workman M, Talbot JN, Hill DK, Le TT. Potency Assessment of CBD Oils by Their Effects on Cell Signaling Pathways. Nutrients. 12. PMID 32019055 DOI: 10.3390/Nu12020357 |
0.277 |
|
| 2020 |
Urasaki Y, Beaumont C, Talbot JN, Hill DK, Le TT. Akt3 Regulates the Tissue-Specific Response to Copaiba Essential Oil. International Journal of Molecular Sciences. 21. PMID 32325885 DOI: 10.3390/Ijms21082851 |
0.269 |
|
| 2013 |
Burke HM, Robinson CM, Wentz B, McKay J, Dexter KW, Pisansky JM, Talbot JN, Zoladz PR. Sex-specific impairment of spatial memory in rats following a reminder of predator stress. Stress (Amsterdam, Netherlands). 16: 469-76. PMID 23550585 DOI: 10.3109/10253890.2013.791276 |
0.269 |
|
| 2011 |
Nolan TL, Lapinsky DJ, Talbot JN, Indarte M, Liu Y, Manepalli S, Geffert LM, Amos ME, Taylor PN, Madura JD, Surratt CK. Identification of a novel selective serotonin reuptake inhibitor by coupling monoamine transporter-based virtual screening and rational molecular hybridization. Acs Chemical Neuroscience. 2: 544-552. PMID 21966587 DOI: 10.1021/Cn200044X |
0.259 |
|
| 1996 |
Yang S, Buxton ILO, Probert CB, Talbot JN, Bradley ME. Evidence for a discrete UTP receptor in cardiac endothelial cells British Journal of Pharmacology. 117: 1572-1578. PMID 8730756 DOI: 10.1111/J.1476-5381.1996.Tb15323.X |
0.259 |
|
| 2018 |
Yellepeddi VK, Zhudeva MY, Movahedi F, Vo A, Phan J, Kirsh RD, Rawlins DB, Talbot JN. Biopharmaceutical Characterization and Oral Efficacy of a New Rapid Acting Antidepressant Ro 25-6981. Journal of Pharmaceutical Sciences. PMID 29800545 DOI: 10.1016/J.Xphs.2018.05.005 |
0.244 |
|
| 2009 |
Doze VA, Handel EM, Jensen KA, Darsie B, Luger EJ, Haselton JR, Talbot JN, Rorabaugh BR. alpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse. Brain Research. 1285: 148-57. PMID 19540213 DOI: 10.1016/J.Brainres.2009.06.035 |
0.223 |
|
| 2007 |
Roman DL, Talbot JN, Roof RA, Sunahara RK, Traynor JR, Neubig RR. Characterization and mechanistic investigation of CCG‐4986, a small molecule RGS4 inhibitor The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A431 |
0.205 |
|
| 2019 |
Riccio KK, Rawlins DB, Talbot JN, Boyd CJ. Demonstration of Smartphones as Viable Tools for Adolescent Substance Use Surveillance. Substance Use & Misuse. 1-4. PMID 31826691 DOI: 10.1080/10826084.2019.1696822 |
0.193 |
|
| 2011 |
Talbot JN. CTOP Xpharm: the Comprehensive Pharmacology Reference. 1-3. DOI: 10.1016/B978-008055232-3.61522-3 |
0.12 |
|
| 2015 |
Talbot JN, Gligorov J, Nataf V, Montravers F, Huchet V, Michaud L, Ohnona J, Balogova S, Cussenot O, Daraï E, Lotz JP, Kerrou K. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone. The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (Aimn) [and] the International Association of Radiopharmacology (Iar), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology. 59: 4-17. PMID 25693420 |
0.116 |
|
| 2013 |
Chereau E, Durand L, Frati A, Prignon A, Talbot JN, Rouzier R. Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model. Anticancer Research. 33: 3015-9. PMID 23898054 |
0.115 |
|
| 2006 |
Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, Gutman F, Grangé JD, Lotz JP, Talbot JN. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 1455-62. PMID 16954553 |
0.114 |
|
| 2014 |
Michaud L, Burgess A, Huchet V, Lefèvre M, Tassart M, Ohnona J, Kerrou K, Balogova S, Talbot JN, Périé S. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? The Journal of Clinical Endocrinology and Metabolism. 99: 4531-6. PMID 25215560 DOI: 10.1210/jc.2014-2821 |
0.114 |
|
| 2015 |
Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, Lefèvre M, Tassart M, Montravers F, Périé S, Talbot JN. A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism: Influence of Thyroid Anomalies. Medicine. 94: e1701. PMID 26469908 DOI: 10.1097/MD.0000000000001701 |
0.114 |
|
| 2006 |
Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, Grahek D, Montravers F, Poupon R, Rosmorduc O. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 33: 1285-9. PMID 16802155 DOI: 10.1007/s00259-006-0164-9 |
0.109 |
|
| 2007 |
Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Seminars in Nuclear Medicine. 37: 420-8. PMID 17920349 DOI: 10.1053/J.Semnuclmed.2007.07.003 |
0.108 |
|
| 2011 |
Alshoukr F, Prignon A, Brans L, Jallane A, Mendes S, Talbot JN, Tourwé D, Barbet J, Gruaz-Guyon A. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors. Bioconjugate Chemistry. 22: 1374-85. PMID 21662976 DOI: 10.1021/bc200078p |
0.107 |
|
| 2005 |
Deniaud-Alexandre E, Touboul E, Lerouge D, Grahek D, Foulquier JN, Petegnief Y, Grès B, El Balaa H, Keraudy K, Kerrou K, Montravers F, Milleron B, Lebeau B, Talbot JN. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers]. Cancer RadiothéRapie : Journal De La SociéTé FrançAise De RadiothéRapie Oncologique. 9: 304-15. PMID 16087377 DOI: 10.1016/j.canrad.2005.07.002 |
0.105 |
|
| 2010 |
Balogova S, Huchet V, Kerrou K, Nataf V, Gutman F, Antoine M, Ruppert AM, Prignon A, Lavolée A, Montravers F, Mayaud C, Cadranel J, Talbot JN. Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nuclear Medicine Communications. 31: 389-97. PMID 20145579 DOI: 10.1097/MNM.0b013e3283369654 |
0.104 |
|
| 2012 |
Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot JN, Montravers F. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nuclear Medicine Communications. 33: 775-9. PMID 22546877 DOI: 10.1097/MNM.0b013e3283543304 |
0.104 |
|
| 2010 |
Arfi J, Kerrou K, Traore S, Huchet V, Bolly A, Antoine M, Delaunois L, Vander Borght T, Talbot JN. F-18 FDG PET/CT findings in pulmonary necrotizing sarcoid granulomatosis. Clinical Nuclear Medicine. 35: 697-700. PMID 20706045 DOI: 10.1097/RLU.0b013e3181e9fade |
0.104 |
|
| 2009 |
Aide N, Poulain L, Briand M, Dutoit S, Allouche S, Labiche A, Ngo-Van Do A, Nataf V, Batalla A, Gauduchon P, Talbot JN, Montravers F. Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. European Journal of Nuclear Medicine and Molecular Imaging. 36: 396-405. PMID 19050878 DOI: 10.1007/s00259-008-0984-x |
0.104 |
|
| 2005 |
Moureau-Zabotto L, Touboul E, Lerouge D, Deniaud-Alexandre E, Grahek D, Foulquier JN, Petenief Y, Grès B, El Balaa H, Kerrou K, Montravers F, Keraudy K, Tiret E, Gendre JP, Grange JD, ... ... Talbot JN, et al. [Impact of computed tomography (CT) and 18F-deoxyglucose positron emission tomography (FDG-PET) image fusion for conformal radiotherapy in esophageal carcinoma]. Cancer RadiothéRapie : Journal De La SociéTé FrançAise De RadiothéRapie Oncologique. 9: 152-60. PMID 16023043 DOI: 10.1016/j.canrad.2005.04.001 |
0.103 |
|
| 2013 |
Metivier D, Montravers F, Balogova S, Talbot JN. 18F-FDG PET/CT uptake due to poly-L-lactic acid facial injections. Nuklearmedizin. Nuclear Medicine. 52: N66-7. PMID 24337016 |
0.103 |
|
| 2011 |
Langsteger W, Balogova S, Huchet V, Beheshti M, Paycha F, Egrot C, Janetschek G, Loidl W, Nataf V, Kerrou K, Pascal O, Cussenot O, Talbot JN. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (Aimn) [and] the International Association of Radiopharmacology (Iar), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology. 55: 448-57. PMID 21738117 |
0.102 |
|
| 2004 |
Plaza P, Montravers F, Aide N, Carrera D, Kerrou K, Ferran N, Grahek D, Talbot JN. [Assessment of a neuroendocrine tumour by 111In-pentetreotid scintigraphy and PET with 18FFDOPA and 18F-FDG]. Revista EspañOla De Medicina Nuclear. 23: 421-4. PMID 15625060 |
0.102 |
|
| 2012 |
Balogova S, Rose J, Alqarni A, Chauchat P, Cross T, Talbot JN, Nataf V. Retrospective study of the consequences of administration of a FDG preparation containing between 5% and 10% of free fluoride (18F) on PET/CT imaging of normal bone and pathologic bone foci. Comparison with a paired group of patients who received a FDG preparation containing less than 5% of free fluoride (18F) | Étude rétrospective des conséquences de l'administration d'une préparation de FDG contenant de 5 % à 10 % de fluorure (18F) libre sur l'imagerie TEP/TDM de l'os sain et des foyers osseux pathologiques. Comparaison avec un gr Medecine Nucleaire. 36: 371-377. DOI: 10.1016/j.mednuc.2012.05.002 |
0.102 |
|
| 2012 |
Balogova S, Paycha F, Kaliska L, Kunikowska J, Talbot JN. Non-FDG PET studies in oncology: Bone PET with fluoride (18F) Nuclear Medicine Review. 15: C52-C60. |
0.101 |
|
| 2011 |
Clarençon F, Larousserie F, Babinet A, Zylbersztein C, Talbot JN, Kerrou K. FDG PET/CT findings in a case of myositis ossificans circumscripta of the forearm. Clinical Nuclear Medicine. 36: 40-2. PMID 21157208 DOI: 10.1097/RLU.0b013e3181feed95 |
0.101 |
|
| 2015 |
Jorgov L, Montravers F, Balogova S, Ragu C, Pacquement H, Leblanc T, Abbou S, Ducou-Lepointe H, Landman-Parker J, Talbot JN. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. PMID 26660144 DOI: 10.1007/s00259-015-3280-6 |
0.101 |
|
| 2004 |
Montravers F, Grahek D, Kerrou K, Younsi N, Petegnief Y, de Beco V, Colombet-Lamau C, Talbot JN. Detection of recurrent colorectal carcinoma by 18F-FDG: comparison of the clinical performances of FDG PET and FDG CDET. Nuclear Medicine Communications. 25: 105-13. PMID 15154697 |
0.101 |
|
| 2008 |
Talbot JN, Chevalme YM. Current evaluation of the clinical utility of fluoromethylcholine-(18F) PET/CT in prostate cancer Brazilian Archives of Biology and Technology. 51: 71-75. DOI: 10.1590/S1516-89132008000700012 |
0.099 |
|
| 2006 |
Talbot JN, Kerrou K, Gutman F, Périé S, Grahek D, Roulet E, Saint Guily JL, Montravers F. [FDG-PET in localization of cancers of unknown primary origin]. Presse MéDicale (Paris, France : 1983). 35: 1371-6. PMID 16969333 |
0.099 |
|
| 2010 |
Talbot JN. [PET/CT in colorectal cancer]. La Revue Du Praticien. 60: 1074-7. PMID 21197736 |
0.099 |
|
| 2014 |
Balogova S, Zakoun JB, Michaud L, Khalil A, Tassart M, Esteso A, Kerrou K, Huchet V, Carette MF, Lotz JP, Talbot JN. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study. Clinical Nuclear Medicine. 39: 951-9. PMID 25140552 DOI: 10.1097/RLU.0000000000000562 |
0.099 |
|
| 2006 |
Gutman F, Aflalo-Hazan V, Kerrou K, Montravers F, Grahek D, Talbot JN. 18F-choline PET/CT for initial staging of advanced prostate cancer. Ajr. American Journal of Roentgenology. 187: W618-21. PMID 17114515 DOI: 10.2214/AJR.05.0437 |
0.098 |
|
| 2015 |
Prignon A, Nataf V, Provost C, Cagnolini A, Montravers F, Gruaz-Guyon A, Lantry LE, Talbot JN, Nunn AD. (68)Ga-AMBA and (18)F-FDG for preclinical PET imaging of breast cancer: effect of tamoxifen treatment on tracer uptake by tumor. Nuclear Medicine and Biology. 42: 92-8. PMID 25459112 DOI: 10.1016/j.nucmedbio.2014.10.003 |
0.098 |
|
| 2012 |
Balogova S, Vasovic M, Vereb M, Kaliska L, Talbot JN. Registered and potential indications of FDG PET/CT in breast carcinoma Archive of Oncology. 20: 152-157. DOI: 10.2298/AOO1204152B |
0.098 |
|
| 2005 |
Bourguet P, Brusco S, Corone C, Devillers A, Foehrenbach H, Lumbroso JD, Maszelin P, Montravers F, Moretti JL, Rain JD, Talbot JN, Carretier J, Leichtnam-Dugarin L, Delavigne V, Philip T, et al. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives]. Bulletin Du Cancer. 92: 723-32. PMID 16123010 |
0.097 |
|
| 2004 |
Jeffry L, Kerrou K, Camatte S, Metzger U, Lelièvre L, Talbot JN, Lecuru F. Endometriosis with FDG uptake on PET. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 117: 236-9. PMID 15541863 DOI: 10.1016/j.ejogrb.2004.04.034 |
0.097 |
|
| 2007 |
Chevalme YM, Montravers F, Vuillez JP, Zanca M, Fallais C, Oustrin J, Talbot JN. FDOPA-(18F): A PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union Brazilian Archives of Biology and Technology. 50: 77-90. |
0.097 |
|
| 2007 |
Aide N, Benayoun M, Kerrou K, Khalil A, Cadranel J, Talbot JN. Impact of [18F]-fluorodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy. The British Journal of Radiology. 80: e67-71. PMID 17548505 DOI: 10.1259/bjr/33076108 |
0.097 |
|
| 2010 |
Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, Huchet V, Ancel D, Grange JD, Rosmorduc O. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1699-706. PMID 20956466 DOI: 10.2967/jnumed.110.075507 |
0.096 |
|
| 2005 |
Moureau-Zabotto L, Touboul E, Lerouge D, Deniaud-Alexandre E, Grahek D, Foulquier JN, Petegnief Y, Grès B, El Balaa H, Kerrou K, Montravers F, Keraudy K, Tiret E, Gendre JP, Grange JD, ... ... Talbot JN, et al. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. International Journal of Radiation Oncology, Biology, Physics. 63: 340-5. PMID 16168829 DOI: 10.1016/j.ijrobp.2005.02.039 |
0.096 |
|
| 2011 |
Vercellino L, Montravers F, de Parades V, Huchet V, Kerrou K, Bauer P, Touboul E, Talbot JN. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma. International Journal of Colorectal Disease. 26: 201-10. PMID 21061012 DOI: 10.1007/s00384-010-1080-9 |
0.096 |
|
| 2006 |
Talbot JN, Petegnief Y, de Beco V, Nataf V, Balard M. [Basics of PET and PET/CT imaging: instrumentation and radiopharmaceuticals for clinical diagnosis]. Presse MéDicale (Paris, France : 1983). 35: 1331-7. PMID 16969329 |
0.096 |
|
| 2015 |
Hacker M, Beyer T, Baum RP, Kalemis A, Lammertsma AA, Lewington V, Talbot JN, Verzijlbergen F. Nuclear medicine innovations help (drive) healthcare (benefits). European Journal of Nuclear Medicine and Molecular Imaging. 42: 173-5. PMID 25416634 DOI: 10.1007/S00259-014-2957-6 |
0.096 |
|
| 2008 |
Balogova S, Périé S, Kerrou K, Grahek D, Montravers F, Angelard B, Susini B, El Chater P, St Guily JL, Talbot JN. Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 10: 364-73. PMID 18668293 DOI: 10.1007/s11307-008-0155-2 |
0.096 |
|
| 2005 |
Talbot JN, Kerrou K, Missoum F, Grahek D, Aide N, Lumbroso J, Montravers F. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 7: 257-61. PMID 16082495 DOI: 10.1007/s11307-005-0006-3 |
0.095 |
|
| 2009 |
Montravers F, Kerrou K, Huchet V, Pascal O, Talbot JN. [FDG PET/CT and childhood Hodgkin lymphoma]. Archives De PéDiatrie : Organe Officiel De La SociéTe FrançAise De PéDiatrie. 16: 669-71. PMID 19541124 DOI: 10.1016/S0929-693X(09)74106-5 |
0.095 |
|
| 2009 |
Arfi J, Kerrou K, Huchet V, Antoine M, Terrioux P, Talbot JN. Scattered multiple pulmonary nodules in a 35-year-old woman disclosing a necrotising sarcoid granulomatosis diagnosed on FDG (18F) PET/CT guided surgical biopsy | Lâcher de ballons chez une femme de 35 ans révélant une granulomatose sarcoïdosique nécrosante diagnostiquée sur biopsie guidée par la TEP/TDM au FDG (18F) Medecine Nucleaire. 33: 410-414. DOI: 10.1016/j.mednuc.2009.04.002 |
0.095 |
|
| 2007 |
Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, Paone G, Talbot JN, Rahmouni A, Meignan M. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 1626-32. PMID 17873129 DOI: 10.2967/jnumed.107.042093 |
0.094 |
|
| 2010 |
Vercellino L, de Parades V, Nataf V, Kerrou K, Huchet V, Bauer P, Pascal O, Touboul E, Montravers F, Talbot JN. Has FDG PET/CT an impact on the management of patients with anal carcinoma? | La TEP/TDM au FDG a-t-elle un impact dans la prise en charge des patients atteints d'un cancer du canal anal ? Medecine Nucleaire. 34: 96-102. DOI: 10.1016/j.mednuc.2009.12.005 |
0.094 |
|
| 2008 |
Clarençon F, Gutman F, Giannesini C, Pénicaud A, Galanaud D, Kerrou K, Marro B, Talbot JN. MRI and FDG PET/CT findings in a case of probable Heidenhain variant Creutzfeldt-Jakob disease. Journal of Neuroradiology. Journal De Neuroradiologie. 35: 240-3. PMID 18466976 DOI: 10.1016/j.neurad.2008.03.001 |
0.094 |
|
| 2007 |
Aide N, Louis MH, Dutoit S, Labiche A, Lemoisson E, Briand M, Nataf V, Poulain L, Gauduchon P, Talbot JN, Montravers F. Improvement of semi-quantitative small-animal PET data with recovery coefficients: a phantom and rat study. Nuclear Medicine Communications. 28: 813-22. PMID 17728612 DOI: 10.1097/MNM.0b013e32822a0f37 |
0.094 |
|
| 2007 |
Chaise C, Itti E, Petegnief Y, Wirquin E, Copie-Bergman C, Farcet JP, Delfau-Larue MH, Meignan M, Talbot JN, Molinier-Frenkel V. [F-18]-Fluoro-2-deoxy-D: -glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model. Cancer Immunology, Immunotherapy : Cii. 56: 1163-71. PMID 17171356 DOI: 10.1007/s00262-006-0265-0 |
0.094 |
|
| 2010 |
Talbot JN. [Diagnostic use of positron emission tomography in France: from the coincidence gamma-camera to mobile hybrid PET/CT devices]. Bulletin De L'AcadéMie Nationale De MéDecine. 194: 1559-76; discussion . PMID 22046717 |
0.093 |
|
| 2014 |
Montravers F, Arnoux JB, Ribeiro MJ, Kerrou K, Nataf V, Galmiche L, Aigrain Y, Bellanné-Chantelot C, Saint-Martin C, Ohnona J, Balogova S, Huchet V, Michaud L, Talbot JN, De Lonlay P. Strengths and limitations of using 18fluorine- fluorodihydroxyphenylalanine PET/CT for congenital hyperinsulinism Expert Review of Endocrinology and Metabolism. 9: 477-485. DOI: 10.1586/17446651.2014.949240 |
0.093 |
|
| 2012 |
Fartoux L, Balogova S, Nataf V, Kerrou K, Huchet V, Rosmorduc O, Talbot JN. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nuclear Medicine Communications. 33: 757-65. PMID 22504293 DOI: 10.1097/MNM.0b013e328350fb9f |
0.092 |
|
| 2008 |
Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, Vaylet C, Rougier P, André T, Gornet JM, Cherqui D, Delbaldo C, Panis Y, Talbot JN, Meignan M, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. British Journal of Cancer. 98: 875-80. PMID 18301402 DOI: 10.1038/sj.bjc.6604263 |
0.091 |
|
| 2009 |
Huchet V, Paycha F, Balogova S, Halimi A, Kerrou K, Pascal O, Montravers F, Talbot JN. Fluoride (18F) PET/CT for the detection of bone metastases of prostate cancer. Description of Fluprostic trial for comparison to whole-body MRI in this indication | TEP/TDM au fluorure (18F) de sodium pour la détection des métastases osseuses du cancer de la prostate. Description de l'étude Fluprostic de comparaison de la TEP/TDM au fluorure (18F) de sodium à l'IRM corps entier dans cette indication Medecine Nucleaire. 33: 388-397. DOI: 10.1016/j.mednuc.2009.05.002 |
0.091 |
|
| 2014 |
Hodolic M, Michaud L, Huchet V, Balogova S, Nataf V, Kerrou K, Vereb M, Fettich J, Talbot JN. Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey. Radiology and Oncology. 48: 20-8. PMID 24587775 DOI: 10.2478/raon-2013-0049 |
0.09 |
|
| 2014 |
Paycha F, Talbot JN. 68Ga: Making it available for diagnostic and theranostic applications. Avoid the pseudo-metastasis pitfall on bone SPECT/CT, or PET/CT. Significance of a prostatic FDG focus | 68Ga: Mise en oeuvre pour des applications diagnostiques et théranostiques. Éviter le piège des pseudo-métastases en TEMP/TDM ou TEP/TDM du squelette. Signification d'un foyer prostatique en TEP au FDG Medecine Nucleaire. 38: 227-228. DOI: 10.1016/j.mednuc.2014.07.010 |
0.09 |
|
| 2012 |
Michaud L, Kerrou K, Lefèvre M, Montravers F, Périé S, Khalil A, Karcenti A, Huchet V, Wartski M, Balogova S, Talbot JN. FDG PET/CT in one case of hibernoma | TEP/TDM au FDG et hibernome : À propos d'un cas Medecine Nucleaire. 36: 408-412. DOI: 10.1016/j.mednuc.2012.05.005 |
0.09 |
|
| 2006 |
Montravers F, Grahek D, Kerrou K, Gutman F, Talbot JN. [Positron emission tomography (PET) in gastrointestinal cancer]. GastroentéRologie Clinique Et Biologique. 30: 737-41. PMID 16801895 |
0.09 |
|
| 2010 |
Balogova S, Nataf V, Gutman F, Huchet V, Kerrou K, Pascal O, Montravers F, Talbot JN. Biological recurrence of prostate cancer: Interest of whole-body fluorocholine (18F) PET/CT | Récidive biologique de cancer de la prostate: Intérêt de la TEP/TDM à la fluorocholine (18F) du corps entier Medecine Nucleaire. 34: 540-545. DOI: 10.1016/j.mednuc.2010.06.001 |
0.089 |
|
| 2007 |
Huchet V, Kerrou K, Derhy S, Assad R, Gutman F, Balogova S, Nataf V, Bizien V, Grahek D, Montravers F, Talbot JN. Fluoromethylcholine-(18F) PET/CT in recurrent prostate cancer imaging: The basic for a national cooperative study | TEP/TDM à la fluorométhylcholine-(18F) dans l'imagerie de la récidive du cancer de la prostate : jalons pour un PHRC national Medecine Nucleaire. 31: 338-344. DOI: 10.1016/j.mednuc.2007.05.003 |
0.089 |
|
| 2012 |
Tardivel AM, Wartski M, Michaud L, Talbot JN, Kerrou K. Incidental discovery of an asymptomatic mesenteric mass with rapid growth: Role of FDG PET/CT in the patient's management | Découverte fortuite d'une masse mésentérique asymptomatique d'évolution rapide : Rôle de la TEP/TDM au FDG dans la prise en charge du patient Medecine Nucleaire. 36: 403-407. DOI: 10.1016/j.mednuc.2012.05.001 |
0.088 |
|
| 2008 |
Talbot JN, Montravers F, Gutman F, Kerrou K, Huchet V, Grahek D, Andre T, Houry S, Touboul E, Rosmorduc O, Poupon R, Ruszniewski P, Rougier P, Grange JD. [PET and digestive cancers]. Presse Mã©Dicale (Paris, France : 1983). 37: e1-e24. PMID 17951024 DOI: 10.1016/j.lpm.2007.03.048 |
0.088 |
|
| 2005 |
Deniaud-Alexandre E, Touboul E, Lerouge D, Grahek D, Foulquier JN, Petegnief Y, Grès B, El Balaa H, Keraudy K, Kerrou K, Montravers F, Milleron B, Lebeau B, Talbot JN. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 63: 1432-41. PMID 16125870 DOI: 10.1016/j.ijrobp.2005.05.016 |
0.087 |
|
| 2005 |
Aide N, Deux JF, Peretti I, Mabille L, Mandet J, Callard P, Talbot JN. Persistent foreign body reaction around inguinal mesh prostheses: a potential pitfall of FDG PET. Ajr. American Journal of Roentgenology. 184: 1172-7. PMID 15788589 DOI: 10.2214/ajr.184.4.01841172 |
0.087 |
|
| 2014 |
Lecouvet FE, Talbot JN, Messiou C, Bourguet P, Liu Y, de Souza NM. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. European Journal of Cancer (Oxford, England : 1990). 50: 2519-31. PMID 25139492 DOI: 10.1016/J.Ejca.2014.07.002 |
0.087 |
|
| 2006 |
Merheb C, Nicol S, Petegnief Y, Talbot JN, Buvat I. Assessment of the Mosaic animal PET system response using list-mode data for validation of GATE Monte Carlo modelling Nuclear Instruments and Methods in Physics Research, Section a: Accelerators, Spectrometers, Detectors and Associated Equipment. 569: 220-224. DOI: 10.1016/j.nima.2006.08.125 |
0.086 |
|
| 2008 |
Montravers F, de Bazelaire C, Kerrou K, Farges C, Huchet V, Talbot JN, Frija J, de Kerviler E. [Imaging and PET-CT of adult and childhood lymphoma]. Journal De Radiologie. 89: 371-84; quiz 385-6. PMID 18408639 DOI: JR-03-2008-89-3-C2-0221-0363-101019-200800660 |
0.085 |
|
| 2008 |
Touboul E, Huguet F, Talbot JN. [Use of PET for staging, treatment evaluation, and follow-up in esophageal cancers]. Cancer RadiothéRapie : Journal De La SociéTé FrançAise De RadiothéRapie Oncologique. 12: 633-9. PMID 18693057 DOI: 10.1016/j.canrad.2008.07.001 |
0.084 |
|
| 2010 |
Nataf V, Kerrou K, Balogova S, Pene F, Huchet V, Gutman F, Prignon A, Muresan IP, Giannesini C, Izrael V, Schlienger M, Talbot JN. [Fluoroethylthyrosine 18F PET in the detection of brain tumours]. Bulletin Du Cancer. 97: 495-506. PMID 20374979 DOI: 10.1684/bdc.2010.1078 |
0.083 |
|
| 2006 |
Talbot JN, Montravers F, Grahek D, Kerrou K, Gutman F, Cailleux N. [FDG PET and its impact on patient's management in oncology]. Presse MéDicale (Paris, France : 1983). 35: 1339-46. PMID 16969330 |
0.083 |
|
| 2013 |
Slavikova K, Montravers F, Treglia G, Kunikowska J, Kaliska L, Vereb M, Talbot JN, Balogova S. What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma? Current Radiopharmaceuticals. 6: 96-105. PMID 23745775 |
0.08 |
|
| 2013 |
Balogova S, Huchet V, Egrot C, Michaud L, Paycha F, Kerrou K, Montravers F, Cussenot O, Talbot JN. Effect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: comparison with 18F-fluoride uptake. Clinical Nuclear Medicine. 38: 200-2. PMID 23354033 DOI: 10.1097/RLU.0b013e31827a2294 |
0.08 |
|
| 2006 |
Aflalo-Hazan V, Gutman F, Raileanu I, Frétault J, Kerrou K, Grahek D, Montravers F, Talbot JN. [18F-FDG PET and bone scintigraphy to search for bone metastasis of lung cancer]. Revue De Pneumologie Clinique. 62: 164-9. PMID 16840993 |
0.079 |
|
| 2005 |
Grahek D, Barranger E, Daraï E, Uzan S, Talbot JN. [Role of [18F]-fluorodeoxyglucose positron emission tomography for the initial detection, staging, search for recurrences and restaging of gynaecological and breast cancers]. GynéCologie, ObstéTrique & Fertilité. 33: 371-81. PMID 15927502 DOI: 10.1016/j.gyobfe.2005.01.005 |
0.079 |
|
| 2006 |
Talbot JN, Montravers F, Younsi N, Zanotti-Fregonara P, Zanotti P, Grahek D, Kerrou K, Gutman F, Périé S, Maurel G, Saint Guily JL, Devaux JY, Duron F. [PET in thyroid cancers]. Presse MéDicale (Paris, France : 1983). 35: 1377-85. PMID 16969334 |
0.079 |
|
| 2006 |
Nataf V, Balard M, de Beco V, Kerrou K, Gutman F, Grahek D, Montravers F, Talbot JN. Safety of 18F-DOPA injection for PET of carcinoid tumor. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 1732; author reply 1. PMID 17015913 |
0.079 |
|
| 2006 |
Talbot JN, Périé S, Kerrou K, Montravers F, Balogova S, Grahek D, Gutman F, Saint Guily JL. [PET in head and neck cancers]. Presse MéDicale (Paris, France : 1983). 35: 1355-69. PMID 16969332 |
0.079 |
|
| 2014 |
Michaud L, Huchet V, Talbot JN, Paycha F. Bifocal ribs hot spots on bone PET with sodium fluoride (18F) in the staging of a prostate cancer | Hyperfixations costales bifocales découvertes à la TEP au fluorure (18F) de sodium lors de la stadification d'un cancer de la prostate Medecine Nucleaire. 38: 257-265. DOI: 10.1016/j.mednuc.2014.07.006 |
0.078 |
|
| 2007 |
Clarençon F, Kerrou K, Gutman F, Chevallier D, Montravers F, Talbot JN. Asymmetric F-18 fluorocholine uptake of submaxillary glands revealing intraglandular lithiasis. Clinical Nuclear Medicine. 32: 165-7. PMID 17242581 DOI: 10.1097/01.rlu.0000252183.30491.55 |
0.078 |
|
| 2014 |
Talbot JN, Michaud L, Grange JD, Rosmorduc O, Balogova S. Use of choline PET for studying hepatocellular carcinoma Clinical and Translational Imaging. 2: 103-113. DOI: 10.1007/s40336-014-0055-1 |
0.077 |
|
| 2006 |
Talbot JN, Grahek D. [Update of 'standards, options and recommendations' for FDG-PET in breast and gynaecological cancers]. GynéCologie, ObstéTrique & Fertilité. 34: 434-6. PMID 16677841 DOI: 10.1016/j.gyobfe.2006.03.015 |
0.077 |
|
| 2007 |
Périé S, Hugentobler A, Susini B, Balogova S, Grahek D, Kerrou K, Montravers F, Chater PE, St Guily JL, Talbot JN. Impact of FDG-PET to detect recurrence of head and neck squamous cell carcinoma. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 137: 647-53. PMID 17903585 DOI: 10.1016/j.otohns.2007.05.063 |
0.076 |
|
| 2009 |
Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P, Rougier P, Duron F, Bouchard P, Grangé JD, Houry S, Talbot JN. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. The Journal of Clinical Endocrinology and Metabolism. 94: 1295-301. PMID 19141589 DOI: 10.1210/jc.2008-1349 |
0.075 |
|
| 2006 |
Talbot JN, Kerrou K, Grahek D, Balogova S, Gounant V, Lavole A, Gutman F, Aflalo-Hazan V, Raileanu I, Montravers F, Mayaud C. [PET in primary pulmonary or pleural cancer]. Presse MéDicale (Paris, France : 1983). 35: 1387-400. PMID 16969335 |
0.075 |
|
| 2012 |
Mammar H, Kerrou K, Nataf V, Pontvert D, Clemenceau S, Lot G, George B, Polivka M, Mokhtari K, Ferrand R, Feuvret L, Habrand JL, Pouysségur J, Mazure N, Talbot JN. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting. International Journal of Radiation Oncology, Biology, Physics. 84: 681-7. PMID 22391104 DOI: 10.1016/j.ijrobp.2011.12.047 |
0.075 |
|
| 2013 |
Gillebert Q, Michaud L, Audard V, Talbot JN, Kerrou K. Accidental detection of an extra-articular pigmented villonodular synovitis located in psoas muscle on 18F-fluorodesoxyglucose positron emission tomography | Détection fortuite d'une synovite villonodulaire extra-articulaire du muscle psoas en tomographie par émission de positons au 18F-fluorodésoxyglucose Medecine Nucleaire. 37: 299-303. DOI: 10.1016/j.mednuc.2013.06.005 |
0.074 |
|
| 2011 |
Gaura-Schmidt V, Garderet L, Maurel G, Paycha F, Keller I, Talbot JN, Devaux JY. Value of PET/CT for initial work-up and follow-up of bone lesions in multiple myeloma | Intérêt de la TEP/TDM dans le bilan d'extension et le suivi des lésions osseuses du myélome multiple Medecine Nucleaire. 35: 239-254. DOI: 10.1016/j.mednuc.2011.02.012 |
0.073 |
|
| 2010 |
Margery J, Milleron B, Vaylet F, Grahek D, Lebeau B, Mangiapan G, Bonardel G, de Labriolle-Vaylet C, Meignan M, Carette MF, Talbot JN, Housset B. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study]. Revue De Pneumologie Clinique. 66: 313-20. PMID 21087727 DOI: 10.1016/j.pneumo.2010.07.015 |
0.072 |
|
| 2009 |
Paycha F, Mortier E, Sassi R, Mahjoub WK, Huchet V, Talbot JN. [Osseous Kaposi sarcoma without contiguous cutaneous lesion: interest of positron emission tomography imaging with Fluorodeoxyglucose-(18F)]. Presse MéDicale (Paris, France : 1983). 38: 327-33. PMID 18977631 DOI: 10.1016/j.lpm.2008.04.010 |
0.07 |
|
| 2014 |
Montravers F, Nataf V, Bartovic M, Cich D, Chomet M, Cross T, Géraudie B, Chipan AS, Balogova S, Talbot JN. PET imaging of neuroendocrine tumours of the small intestine | La TEP des tumeurs neuroendocrines de l'intestin grêle Medecine Nucleaire. 38: 235-239. DOI: 10.1016/j.mednuc.2014.07.004 |
0.07 |
|
| 2006 |
Talbot JN, Kerrou K, Gault N, Gutman F, Grahek D, Touboul E, Schlienger M, Montravers F. [PET and malignant cerebral tumors]. Presse MéDicale (Paris, France : 1983). 35: 1347-53. PMID 16969331 |
0.068 |
|
| 2012 |
Balogova S, Cussenot O, Pascal O, Kerrou K, Viglietti D, Egrot C, Nataf V, Huchet V, Michaud L, Talbot JN. Consequence of pegfilgrastim treatment on fluorocholine (18F) uptake by bone marrow | Effet du traitement par pegfilgrastim sur la fixation de la fluorocholine (18F) par la moelle osseuse Medecine Nucleaire. 36: 413-418. DOI: 10.1016/j.mednuc.2012.05.011 |
0.068 |
|
| 2005 |
Perrotin C, Lemeunier P, Grahek D, Molina T, Petino A, Alifano M, Bellenot F, Magdeleinat P, Talbot JN, Regnard JF. [Results of FDG-PET scanning in the pre-operative staging of broncho-pulmonary tumors]. Revue Des Maladies Respiratoires. 22: 579-85. PMID 16294177 |
0.068 |
|
| 2009 |
Montravers F, Nataf V, Balogova S, Kerrou K, Huchet V, Pascal O, Talbot JN. Positron emission tomography and specific radiopharmaceuticals in oncology | Tomographie d'émission de positons et radiopharmaceutiques spécifiques en oncologie : exemples d'application Medecine Nucleaire. 33: 152-160. DOI: 10.1016/j.mednuc.2009.01.006 |
0.068 |
|
| 2006 |
Talbot JN. Principles of positron emission tomography and importance in head and neck cancers | Principes de la tomographie par émission de positons et intérêt dans les cancers des voies aérodigestives supérieures Revue Du Praticien. 56: 1646-1647. |
0.067 |
|
| 2014 |
Hodolic M, Huchet V, Balogova S, Michaud L, Kerrou K, Nataf V, Cimitan M, Fettich J, Talbot JN. Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radiology and Oncology. 48: 228-34. PMID 25177236 DOI: 10.2478/raon-2013-0075 |
0.067 |
|
| 2007 |
Talbot JN, Kerrou K, Montravers F, Nataf V, Chevalme Y. FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines. European Journal of Nuclear Medicine and Molecular Imaging. 34: 1131-2; author reply. PMID 17437107 DOI: 10.1007/s00259-007-0400-y |
0.066 |
|
| 2011 |
Talbot JN. DAMGO Xpharm: the Comprehensive Pharmacology Reference. 1-3. DOI: 10.1016/B978-008055232-3.61541-7 |
0.066 |
|
| 2013 |
Ohnona J, Michaud L, Balogova S, Paycha F, Nataf V, Chauchat P, Talbot JN, Kerrou K. Can we achieve a radionuclide radiation dose equal to or less than that of 99mTc-hydroxymethane diphosphonate bone scintigraphy with a low-dose 18F-sodium fluoride time-of-flight PET of diagnostic quality? Nuclear Medicine Communications. 34: 417-25. PMID 23470463 DOI: 10.1097/MNM.0b013e32835fcd9d |
0.064 |
|
| 2010 |
de Prost N, Kerrou K, Sibony M, Talbot JN, Wislez M, Cadranel J. Fluorine-18 fluorodeoxyglucose with positron emission tomography revealed bone marrow involvement in sarcoidosis patients with anaemia. Respiration; International Review of Thoracic Diseases. 79: 25-31. PMID 19246880 DOI: 10.1159/000204901 |
0.064 |
|
| 2007 |
Talbot JN, Gutman F, Huchet V, Kerrou K, Balogova S, Kerrouche N, Montravers F, Grahek D, Cussenot O, Gattegno B, Thibault P. [Clinical usefulness of positron emission tomography in prostate cancer]. Presse MéDicale (Paris, France : 1983). 36: 1794-806. PMID 17524607 DOI: 10.1016/j.lpm.2007.02.030 |
0.064 |
|
| 2011 |
Talbot JN. DPDPE Xpharm: the Comprehensive Pharmacology Reference. 1-3. DOI: 10.1016/B978-008055232-3.61654-X |
0.063 |
|
| 2014 |
Kaliska L, Balogova S, Kerrou K, Michaud L, Huchet V, Bartovic M, Ohnona J, Talbot JN. Significance of high prostate fluorodeoxyglucose (18F) uptake in a patient with no history of prostate cancer. Clinical cases, review and meta-analysis of literature | Signification d'une hyperfixation prostatique du fluorodésoxyglucose (18F) chez un patient sans antécédent de cancer de la prostate. Cas cliniques, revue et méta-analyse de la littérature Medecine Nucleaire. 38: 266-274. DOI: 10.1016/j.mednuc.2014.07.001 |
0.062 |
|
| 2012 |
Balogova S, Kobetz A, Huchet V, Michaud L, Kerrou K, Paycha F, Nataf V, Idir Z, Hodolic M, Vereb M, Montravers F, Talbot JN. Evolution of the prescription of nuclear medicine examinations in prostate cancer since the registration of fluorocholine (18F): A two-year survey at hôpital Tenon | Évolution de la demande des examens de médecine nucléaire pour cancer de la prostate depuis l'enregistrement de la fluorocholine (18F) : Analyse sur deux ans à l'hôpital Tenon Medecine Nucleaire. 36: 363-370. DOI: 10.1016/j.mednuc.2012.04.004 |
0.061 |
|
| 2010 |
Balogova S, Bumsel F, Kerrou K, Huchet V, Nataf V, Mal F, Gutman F, Montravers F, Talbot JN. Fluorocholine(18F) has a clinical usefulness in prostate cancer and in hepatocellular carcinoma... sometimes in the same patient | La fluorocholine(18F) a une utilité clinique dans le cancer de la prostate et le carcinome hépatocellulaire parfois chez le même malade Medecine Nucleaire. 34: 378-382. DOI: 10.1016/j.mednuc.2010.05.007 |
0.061 |
|
| 2008 |
Huchet V, Kerrou K, Balogova S, Nataf V, Montravers F, Talbot JN. Positron emission tomography and prostate cancer | Tomographie par émission de positons et cancer de la prostate Medecine Nucleaire. 32: 409-417. DOI: 10.1016/j.mednuc.2008.06.003 |
0.059 |
|
| 2007 |
Merheb C, Petegnief Y, Talbot JN. Full modelling of the MOSAIC animal PET system based on the GATE Monte Carlo simulation code. Physics in Medicine and Biology. 52: 563-76. PMID 17228105 DOI: 10.1088/0031-9155/52/3/002 |
0.059 |
|
| 2013 |
Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, Montravers F. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. European Journal of Nuclear Medicine and Molecular Imaging. 40: 943-66. PMID 23417499 DOI: 10.1007/s00259-013-2342-x |
0.059 |
|
| 2006 |
Barry B, Darras J, Dassonville O, Dehesdin D, Dessard-Diana B, Dufour X, Hans S, Lafarge D, De Raucourt D, Laporte H, Marandas P, Piekarski JD, Righini CA, Salvan D, Bachmann P, ... ... Talbot JN, et al. Post-therapeutic follow-up of head and neck cancers of adults: Long text | Suivi post-thérapeutique des carcinomes épidermoïdes des voies aérodigestives supérieures de l'adulte: Texte long Annales D'Oto-Laryngologie Et De Chirurgie Cervico-Faciale. 123: 240-279. PMID 17185921 |
0.058 |
|
| 2005 |
Aflalo-Hazan V, Gutman F, Kerrou K, Montravers F, Grahek D, Talbot JN. Increased FDG uptake by bone marrow in major beta-thalassemia. Clinical Nuclear Medicine. 30: 754-5. PMID 16237306 |
0.058 |
|
| 2010 |
Balogova S, Sauer AM, Périé S, Dudczak J, Nataf V, Pascal O, Kerrou K, Huchet V, Montravers F, Lacau St-Guily J, Talbot JN. Are PTH plasma levels useful for the selection of patients with secondary hyperparathyroidism for preoperative MIBI (99mTc)/123I dual-isotope scintigraphy? | La concentration plasmatique de PTH permet-elle de sélectionner les patients atteints d'hyperparathyroïdie secondaire pour bénéficier de la scintigraphie double isotope MIBI (99mTc)/123I préopératoire ? Medecine Nucleaire. 34: 388-392. DOI: 10.1016/j.mednuc.2010.05.010 |
0.053 |
|
| 2013 |
Balogova S, Michaud L, Vereb M, Decazes P, Huchet V, Kerrou K, Fartoux L, Montravers F, Rosmorduc O, Talbot JN. 18F-fluorocholine may be taken-up by brown adipose tissue. Nuklearmedizin. Nuclear Medicine. 52: N3-4. PMID 24395333 |
0.048 |
|
| 2008 |
Vercellino L, Nataf V, Montravers F, Esteso A, Huchet V, Kerrou K, Pascal O, Lotz JP, Talbot JN. DOTATOC-(68Ga) for PET imaging of endocrine digestive tumours: Case report and literature review | Le DOTATOC-(68Ga) pour l'imagerie TEP des tumeurs endocrines digestives : présentation d'un cas et revue de la littérature Medecine Nucleaire. 32: 374-380. DOI: 10.1016/j.mednuc.2008.05.005 |
0.047 |
|
| 2007 |
Sézeur A, Châtelet FP, Cywiner Ch, de Labriolle-Vaylet C, Chastang C, Billotey C, Malafosse M, Gallot D, Betton P, Montravers F, Carvajal-Gonzalez S, Askienazy S, Talbot JN, Rain JD, Milhaud G, et al. Pathology underrates colon cancer extranodal and nodal metastases; ex vivo radioimmunodetection helps staging. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5592s-5597s. PMID 17875794 DOI: 10.1158/1078-0432.CCR-07-1235 |
0.045 |
|
| 2011 |
Schroeder JW, Talbot JN. UFP-101 Xpharm: the Comprehensive Pharmacology Reference. 1-6. DOI: 10.1016/B978-008055232-3.63519-6 |
0.039 |
|
| 2021 |
Chen AMH, Sweeney M, Sprague JE, Dowling TC, Durst SW, Eberle MM, Stolte SK, Talbot JN. Stimulating and sustaining scholarly activity at teaching-intensive institutions. Currents in Pharmacy Teaching & Learning. 13: 228-237. PMID 33641732 DOI: 10.1016/j.cptl.2020.10.005 |
0.036 |
|
| 2011 |
Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities. The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (Aimn) [and] the International Association of Radiopharmacology (Iar), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology. 55: 374-410. PMID 21738113 |
0.036 |
|
| 2004 |
Răileanu I, Rusu V, Talbot JN, Aide N, Hugentobler A, Montravers F, Grahek D, Kerrou K. [Correlation in imaging techniques for the early detection of bone metastases in a case of breast cancer]. Revista Medico-Chirurgicală̆ a Societă̆ţ̜Ii De Medici ş̧I Naturaliş̧Ti Din Iaş̧I. 108: 210-3. PMID 15688788 |
0.035 |
|
| 2004 |
Răileanu I, Grahek D, Rusu V, Montravers F, Aide N, Kerrou K, Talbot JN. [Role of radioisotopic investigations in breast cancer diagnosis and follow-up]. Revista Medico-Chirurgicală̆ a Societă̆ţ̜Ii De Medici ş̧I Naturaliş̧Ti Din Iaş̧I. 108: 251-62. PMID 15688795 |
0.033 |
|
| 2011 |
Mansi L, Talbot JN. Bone metastases, 2011: an old and new field of interest for diagnostic and therapeutic nuclear medicine. The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (Aimn) [and] the International Association of Radiopharmacology (Iar), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology. 55: 335-6. PMID 21738110 |
0.031 |
|
| 2009 |
Chaumet-Riffaud P, Cachin F, Couturier O, Desruet MD, Kraeber-Bodéré F, Talbot JN, Vuillez JP. Clinical trials in nuclear medicine: Present and future | Les essais cliniques en médecine nucléaire : état et perspectives Medecine Nucleaire. 33: 296-304. DOI: 10.1016/j.mednuc.2009.03.001 |
0.03 |
|
| 2005 |
Périé S, Fessi H, Tassart M, Younsi N, Poli I, St Guily JL, Talbot JN. Usefulness of combination of high-resolution ultrasonography and dual-phase dual-isotope iodine 123/technetium Tc 99m sestamibi scintigraphy for the preoperative localization of hyperplastic parathyroid glands in renal hyperparathyroidism. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 45: 344-52. PMID 15685513 |
0.027 |
|
| 2011 |
Schroeder JW, Talbot JN. TIPP-psi Xpharm: the Comprehensive Pharmacology Reference. 1-4. DOI: 10.1016/B978-008055232-3.62770-9 |
0.024 |
|
| 2014 |
Chomet M, Cross T, Géraudie B, Chipan AS, Talbot JN, Nataf V. Gallium-68: Practical considerations to allow successful clinical applications in a nuclear medicine department | Gallium-68: Considérations pratiques pour le succès des applications cliniques au sein d'un service de médecine nucléaire Medecine Nucleaire. 38: 229-234. DOI: 10.1016/j.mednuc.2014.07.003 |
0.023 |
|
| 2020 |
Gonzalez E, Glick JA, Shan G, Talbot JN. Economic and workload impact of therapeutic interchange of inhaler medications and nebulizer solutions. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. PMID 33103194 DOI: 10.1093/ajhp/zxaa343 |
0.022 |
|
| 2004 |
Barranger E, Montravers F, Kerrou K, Marpeau O, Raileanu I, Antoine M, Talbot JN, Uzan S. Contralateral axillary sentinel lymph node drainage in breast cancer: a case report. Journal of Surgical Oncology. 86: 167-9. PMID 15170657 DOI: 10.1002/jso.20056 |
0.016 |
|
| 2012 |
Cross T, Rose J, Mai Ba CU, Montravers F, Talbot JN, Nataf V. Preparation and quality control of edotreotide gallium-68 (DOTATOC ( 68Ga)) | Préparation et contrôle de qualité de la solution injectable de gallium-68 édotréotide (DOTATOC ( 68Ga)) Medecine Nucleaire. 36: 419-423. DOI: 10.1016/j.mednuc.2012.05.009 |
0.012 |
|
| 2011 |
Talbot JN. JTC-801 Xpharm: the Comprehensive Pharmacology Reference. 1-4. DOI: 10.1016/B978-008055232-3.63521-4 |
0.01 |
|
| 2011 |
Talbot JN. Peptide III-BTD Xpharm: the Comprehensive Pharmacology Reference. 1-4. DOI: 10.1016/B978-008055232-3.63520-2 |
0.01 |
|
| 2011 |
Talbot JN. J113397 Xpharm: the Comprehensive Pharmacology Reference. 1-3. DOI: 10.1016/B978-008055232-3.61973-7 |
0.01 |
|
| Hide low-probability matches. |